Mezigdomide, Carfilzomib, and Dexamethasone (Mezikd) vs Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 SUCCESSOR-2 Trial (IMS 2026) - Sep 11, 2026 - Abstract #PA-305; Pres time: Sep 25, 2026; P3 | "Introduction: Patients (pts) entering second-line treatment (tx) are increasingly anti-CD38 mAb- and lenalidomide (LEN)-exposed, limiting tx options...Median (range) age was 68 (30–85) y with 25.1% of pts ≥75 y; median (range) number of prior LOTs was 2 (1–9); 92.1% of pts were triple-class-exposed, with 85.8% refractory to an anti-CD38 mAb and 75.8% to LEN; 37.2% were exposed to pomalidomide and 7.3% to anti-BCMA tx... MeziKd showed a clinically meaningful PFS benefit as early as first relapse in predominantly triple-class-exposed, anti-CD38 mAb- and LEN-refractory pts, a population with significant unmet need. These data support Mezi, a potent oral tx with a predictable and manageable safety profile, as a readily accessible potential new standard of care for RRMM across multiple settings."
P3 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • IKZF1
|
|
Meletios A. Dimopoulos1; Fredrik Schjesvold2; Chengcheng Fu3; Monique A. Hartley-Brown4; Cesar Augusto Gomez5; Donna Reece6; Gabor Mikala7; Omar Alkharabsheh8; Christopher Parrish9; Darrell White10; Hang Quach11; Claudio Cerchione12; Vania Hungria13; Amitabha Mazumder14; Marc S. Raab15; Abstracts S218 23rd International Myeloma Society Annual Meeting September 2026 Albert Oriol16; Zehua Zhou17; Alberto Rocci18; Brian Yu17; Paul G. Richardson4
|